LRMR LRMR

Larimar Therapeutics Stock Price

1.97
0.01 (0.51%)
Upgrade to Real-Time
Regular Market
1.97
Volume 69
Bid Price 1.96
Ask Price 2.27
News -
Day High 1.97

Low
1.90

52 Week Range

High
15.2581

Day Low 1.88
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Larimar Therapeutics Inc LRMR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.51% 1.97 09:30:55
Open Price Low Price High Price Close Price Prev Close
1.97 1.88 1.97 1.96
Trades Volume Avg Volume 52 Week Range
9 69 - 1.90 - 15.2581
Last Trade Time Type Quantity Stock Price Currency
09:30:35 4 $ 2.10 USD

Period:

Draw Mode:

Larimar Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 34.89M 17.71M 11.25M $ - $ - -2.94 -0.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 101.50k 1.20%

more financials information »

Larimar Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LRMR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.132.351.952.0526,264-0.16-7.51%
1 Month2.632.691.902.1715,605-0.66-25.1%
3 Months3.864.201.903.0335,493-1.89-48.96%
6 Months10.9011.051.904.31128,265-8.93-81.93%
1 Year9.4015.25811.906.7696,993-7.43-79.04%
3 Years12.0025.871.909.9989,568-10.03-83.58%
5 Years12.0025.871.909.9989,568-10.03-83.58%

Larimar Therapeutics Description

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.


Your Recent History
NASDAQ
LRMR
Larimar Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.